NCT01261728 - Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 14, 2010

Primary Completion Date

August 6, 2025

Study Completion Date

August 6, 2025

Conditions

Urothelial Carcinoma

Interventions

DRUG

Gemcitabine and Cisplatin

Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.

Trial Locations (9)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau (Consent and Follow-Up only), Uniondale

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

18103

Lehigh Valley Health Network (Data Collection Only), Allentown

85259

Mayo Clinic - Arizona, Scottsdale

Unknown

Hartford Hospital (Data Collection Only), Hartford

07920

Memorial Sloan Kettering at Basking Ridge, Basking Ridge

07645

Memorial Sloan Kettering Bergen, Montvale